Act1 Adaptor Protein Is an Immediate and Essential Signaling Component of Interleukin-17 Receptor
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Interleukin (IL)-17, the founding member of the IL-17 cytokine family, is the hallmark of a novel subset of CD4+ T cells that is regulated by TGFbeta, IL-6, and IL-23. IL-17 plays an important role in promoting tissue inflammation in host defense against infection and in autoimmune diseases. Although IL-17 has been reported to regulate the expression of proinflammatory cytokines, chemokines, and matrix metalloproteinases, the signaling mechanism of IL-17 receptor has not been understood. An earlier study found that IL-17 activates NF-kappaB and MAPK pathways and requires TRAF6 to induce IL-6. However, it is unknown what molecule(s) directly associates with IL-17 receptor to initiate the signaling. We demonstrate here that IL-17 receptor family shares sequence homology in their intracellular region with Toll-IL-1 receptor (TIR) domains and with Act1, a novel adaptor previously reported as an NF-kappaB activator. MyD88 and IRAK4, downstream signaling components of TIR, are not required for IL-17 signaling. On the other hand, Act1 and IL-17 receptor directly associate likely via homotypic interaction. Deficiency of Act1 in fibroblast abrogates IL-17-induced cytokine and chemokine expression, as well as the induction of C/EBPbeta, C/EBPdelta, and IkappaBzeta. Also, absence of Act1 results in a selective defect in IL-17-induced activation of NF-kappaB pathway. These results thus indicate Act1 as a membrane-proximal adaptor of IL-17 receptor with an essential role in induction of inflammatory genes. Our study not only for the first time reveals an immediate signaling mechanism downstream of an IL-17 family receptor but also has implications in therapeutic treatment of various immune diseases.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Act1 is best understood as a nonredundant activator of IL-17RA-dependent signals”
From The IL-17 Family of Cytokines in Health and Disease (2019) · cites this paper as Chang et al., 2006
In the citing paper
“TRAF6 also promotes activation of MAPK/AP1 pathways and the C/EBPβ and δ transcription factors”
From The IL-17 Family of Cytokines in Health and Disease (2019) · cites this paper as Chang et al., 2006
Citations
Cites
A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17
Park, H., Li, Z., Yang, X. O., Chang, S. H., Nurieva, R., Wang, Y.-H., Wang, Y., Hood, L., Zhu, Z., Tian, Q., et al. (2005) · Nature Immunology · doi:10.1038/ni1261 · Cited by 4,265
Self-citationKawai, T., & Akira, S. (2006) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401850 · Cited by 1,810
Th17: An Effector CD4 T Cell Lineage with Regulatory T Cell Ties
Weaver, C. T., Harrington, L. E., Mangan, P. R., Gavrieli, M., & Murphy, K. M. (2006) · Immunity · doi:10.1016/j.immuni.2006.06.002 · Cited by 1,422
Herpesvirus Saimiri encodes a new cytokine, IL-17, which binds to a novel cytokine receptor
Yao, Z., Fanslow, W. C., Seldin, M. F., Rousseau, A.-M., Painter, S. L., Comeau, M. R., Cohen, J. I., & Spriggs, M. K. (1995) · Immunity · doi:10.1016/1074-7613(95)90070-5 · Cited by 994
Cutting Edge: Interleukin 17 Signals through a Heteromeric Receptor Complex
Toy, D., Kugler, D., Wolfson, M., Bos, T. V., Gurgel, J., Derry, J., Tocker, J., & Peschon, J. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.1.36 · Cited by 570
Diversification of T-helper-cell lineages: finding the family root of IL-17-producing cells
Dong, C. (2006) · Nature Reviews Immunology · doi:10.1038/nri1807 · Cited by 487
Self-citationKao, C.-Y., Chen, Y., Thai, P., Wachi, S., Huang, F., Kim, C., Harper, R. W., & Wu, R. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.5.3482 · Cited by 424
Shalom-Barak, T., Quach, J., & Lotz, M. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.42.27467 · Cited by 388
Ruddy, M. J., Wong, G. C., Liu, X. K., Yamamoto, H., Kasayama, S., Kirkwood, K. L., & Gaffen, S. L. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m308809200 · Cited by 364
Schwandner, R., Yamaguchi, K., & Cao, Z. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.7.1233 · Cited by 349
Cited by
Items 201–300 of 366
Pappu, B. P., Angkasekwinai, P., & Dong, C. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.12.003 · Cited by 38
“However, our recent analysis indicated thatMyd88 or IRAK4, essential components of TLR and IL-1R signaling, are not required for IL-17-induced IL-6 expression (Chang et al., 2006).”
BackgroundResultSelf-citationMatsushima, Y., Kikkawa, Y., Takada, T., Matsuoka, K., Seki, Y., Yoshida, H., Minegishi, Y., Karasuyama, H., & Yonekawa, H. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0900694 · Cited by 36
“(27) have demonstrated that the intracellular region of the IL-17R family proteins shares sequence homology with the Toll/IL-1R domain”
BackgroundZepp, J. A., Wu, L., Wen, Q., Ouyang, W., Aronica, M. A., ERZURUM, S. C., & Li, X. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402647 · Cited by 33
“Work from our group and others has shown that the adaptor protein known as activator of NF-kB-1 (ACT1), or CIKS, harbors a SEFIR domain and is a key component in IL-17A and IL-25 signaling (4, 12, 18, 19).”
BackgroundMarks, B. R., & Craft, J. E. (2009) · Seminars in Immunology · doi:10.1016/j.smim.2009.03.001 · Cited by 36
“Upon IL-17RA engagement, signaling via Act1[67] promotes TRAF6 ubiquitination of the receptor[68] and activates the NF-κB transcription factor pathway[67,69-71].”
BackgroundHamilton, T., Li, X., Novotny, M., Pavicic, P. G., Datta, S., Zhao, C., Hartupee, J., & Sun, D. (2011) · Journal of Leukocyte Biology · doi:10.1189/jlb.0811404 · Cited by 32
“It is noteworthy, however, that the Act1/TRAF6 interaction is not disrupted by the IKK deficiency.”
BackgroundInfluentialImmunologic Aspects of Dyslipidemia: a Critical Regulator of Adaptive Immunity and Immune Disorders
Kim, D., Chung, H., Lee, J.-E., Kim, J., Hwang, J., & Chung, Y. (2021) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2021.10.2.184 · Cited by 36
Function of Act1 in IL-17 Family Signaling and Autoimmunity
Wu, L., Zepp, J. A., & Li, X. (2011) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-0106-3_13 · Cited by 36
IL-17 in the Rheumatologist’s Line of Sight
Truchetet, M., Mossalayi, M. D., & Boniface, K. (2013) · BioMed Research International · doi:10.1155/2013/295132 · Cited by 32
“In addition, NFκB activator 1 (Act 1), an adaptor protein for IL-17 receptor, is an essential component of IL-17-mediated signaling and downstream effects [13, 14].”
BackgroundPrimary Immunodeficiencies With Defects in Innate Immunity: Focus on Orofacial Manifestations
Jung, S., Gies, V., Korganow, A., & Guffroy, A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01065 · Cited by 34
“Four of the five causative genes of CMCD are directly involved in IL17 signaling and encode the cytokine IL17F (IL17F), IL17 receptors (IL17RA and IL17RC) (201, 254), and ACT1 (TRAF3IP2), a membraneproximal adaptor of IL17 receptor (255, 256) (Table 8).”
BackgroundCMTM4 is a subunit of the IL-17 receptor and mediates autoimmune pathology
Knizkova, D., Přibíková, M., Draberova, H., Šemberová, T., Trivić, T., Synackova, A., Ujevic, A., Stefanovic, J., Drobek, A., Huranová, M., et al. (2022) · Nature Immunology · doi:10.1038/s41590-022-01325-9 · Cited by 33
Act1-ivating IL-17 inflammation
Hunter, C. A. (2007) · Nature Immunology · doi:10.1038/ni0307-232 · Cited by 33
Exploring IL-17 in spondyloarthritis for development of novel treatments and biomarkers
Groen, S. S., Sinkevičiūtė, D., Bay‐Jensen, A., Thudium, C. S., Karsdal, M. A., Thomsen, S. F., Schett, G. A., & Nielsen, S. H. (2021) · Autoimmunity Reviews · doi:10.1016/j.autrev.2021.102760 · Cited by 35
Lambert, S., Swindell, W. R., Tsoi, L. C., Stoll, S. W., & Elder, J. T. (2017) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2016.12.032 · Cited by 32
“Act1 is recruited to the IL-17 receptor through a SEFIR domain-mediated oligomerization and is essential for appropriate regulation of IL-17emediated signaling (Chang et al., 2006; Qian et al., 2007).”
BackgroundAbdel-Maged, A. E.-S., Gad, A. M., Rashed, L. A., Azab, S. S., Mohamed, E. A., & Awad, A. S. (2020) · Molecular Neurobiology · doi:10.1007/s12035-020-01972-9 · Cited by 32
“Furthermore, IL-17 stimulates microglia and astrocytes resulting in the development or progression of MS through chemokine production and neutrophil recruitment [9].”
BackgroundThe Differential Regulation of Human ACT1 Isoforms by Hsp90 in IL-17 Signaling
Wu, L., Wang, C., Boisson, B., Misra, S., Rayman, P. A., Finke, J. H., Puel, A., Casanova, J., & Li, X. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1400715 · Cited by 29
MicroRNAs and other mechanisms regulate interleukin-17 cytokines and receptors
Yang, X. (2012) · Frontiers in Bioscience-Elite · doi:10.2741/e474 · Cited by 30
Mountz, J. D., Wang, J. H., Xie, S., & Hsu, H. (2011) · PubMed · Cited by 30
Interleukin-17 contributes to cardiovascular diseases
Ding, H., Yang, J., Ding, J., DING, J.-W., Chen, P., & Zhu, P. (2012) · Molecular Biology Reports · doi:10.1007/s11033-012-1580-5 · Cited by 30
“Recent studies have shown that Act-1(the adaptor protein NF-jB activator 1) plays an important role in IL-17-dependent signaling [36–38].”
BackgroundCould the inhibition of IL-17 or IL-18 be a potential therapeutic opportunity for gastric cancer?
Nguyen, P. M., & Putoczki, T. L. (2018) · Cytokine · doi:10.1016/j.cyto.2018.01.008 · Cited by 28
Novel therapeutic targets along the Th17 pathway
Ouyang, W., Filvaroff, E. H., Hu, Y., & Grogan, J. L. (2009) · European Journal of Immunology · doi:10.1002/eji.200839105 · Cited by 27
Ho, A. W., Garg, A. V., Monin, L., Simpson-Abelson, M. R., Kinner, L. B., & Gaffen, S. L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0070168 · Cited by 26
Niu, J., Guo, Y., Jing, G., Wang, H., Yang, L., Li, Y., Gao, Y., Wang, H., Li, A., Xu, X., et al. (2023) · Advanced Functional Materials · doi:10.1002/adfm.202305042 · Cited by 27
Life before seventeen: cloning of the IL-17 receptor
Gaffen, S. L. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1102576 · Cited by 22
“Proof that Act1 was indeed essential for IL-17R signaling soon followed with studies of EAE and IL-17 signaling in Act1 mice (16, 17).”
BackgroundPanagiotidis, G., Vásquez‐Pacheco, E., Chu, X., Seeger, W., Agha, E. E., Bellusci, S., & Lingampally, A. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1609509 · Cited by 25
Ryzhakov, G., Blazek, K. D., & Udalova, I. A. (2011) · Journal of Molecular Evolution · doi:10.1007/s00239-011-9450-7 · Cited by 23
“IRAK1 can in turn recruit TRAF6 via its own TRAF6 binding sites.”
BackgroundInfluentialTRAF3IP2 mediates atherosclerotic plaque development and vulnerability in ApoE mice
Sakamuri, S. S. V. P., Higashi, Y., Sukhanov, S., Siddesha, J. M., Delafontaine, P., Siebenlist, U. K., & Chandrasekar, B. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.05.029 · Cited by 23
“It plays a critical role in IL-17 signaling, as it directly interacts with the IL-17 receptor to activate various downstream inflammatory pathways (7).”
BackgroundOh, S., Shim, M., Son, M., Jang, J. T., Son, K. H., & Byun, K. (2021) · Antioxidants · doi:10.3390/antiox10020298 · Cited by 24
“For NF-κB activation, IL-17RA associates with an adaptor protein, nuclear factor-kappa B activator 1 (ACT1)/ tumor necrosis factor receptor-associated factor 3 interacting protein 2 (TRAF3IP2) [15,16], and TNF receptor-associated factor 6 (TRAF6) [14].”
BackgroundA two phase regulation of bone regeneration: IL-17F mediates osteoblastogenesis via C/EBP-β in vitro
Wang, Y., Kim, J., Chan, A., Whyne, C. M., & Nam, D. (2018) · Bone · doi:10.1016/j.bone.2018.07.007 · Cited by 25
Heo, Y., Oh, H., Jung, Y. O., Cho, M., Lee, S.-Y., Yu, J.-G., Park, M., Kim, H., Lee, S., Park, S., et al. (2011) · Arthritis Research & Therapy · doi:10.1186/ar3398 · Cited by 23
“The absence of Act1 results in a selective deficiency of IL-17-induced activation of the NF- B pathway [30].”
BackgroundA Novel Nuclear Function for the Interleukin-17 Signaling Adaptor Protein Act1
Velichko, S., Zhou, X., Zhu, L., Anderson, J. D., Wu, R., & Chen, Y. (2016) · PLoS ONE · doi:10.1371/journal.pone.0163323 · Cited by 21
“It was subsequently shown that Act1 could bind to several IL-17 receptor family members, via homotypic interactions between their respective SEFIR domains [16, 22].”
BackgroundsiRNA-Act1 Inhibits the Function of IL-17 on Lung Fibroblasts via the NF-κB Pathway
Dong, Z., Yang, Y., Zhang, T., Li, Y., Kang, Q., Lei, W., Cao, Y., Niu, X., Wang, D., & Tai, W. (2013) · Respiration · doi:10.1159/000348403 · Cited by 21
Urabe, S., Isomoto, H., Ishida, T., Maeda, K., Inamine, T., Kondo, S., Higuchi, N., Sato, K., Uehara, R., Yajima, H., et al. (2015) · BioMed Research International · doi:10.1155/2015/416838 · Cited by 21
“This signaling pathway eventually leads to the production of proinflammatory cytokines through NF-κB [8–10, 22–24].”
BackgroundZhao, L., Wang, Z., Tan, Y., Ma, J., Huang, W., Zhang, X., Jin, C., Zhang, T., Liu, W., & Yang, Y. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.115039 · Cited by 22
Feng, Y., Zheng, C., Zhou, Z., Xiong, H., Feng, F., Xie, F., & Wu, Z. (2019) · Experimental Cell Research · doi:10.1016/j.yexcr.2019.111554 · Cited by 20
Li, H., Zhou, Z., Tai, W., Feng, W.-Y., Zhang, D., Gu, X., & Yang, R. (2015) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029615618022 · Cited by 20
“Number of patients 165 149 Gender (Male: female) 58:107 46:103 Age at diagnosis median (range), year 29 (2-79) Child-onset ITP (age at diagnosis<18) 49 Adult-onset ITP (age at diagnosis 18) 116 Disease course median (range), month 12 (0.”
BackgroundYang, Y., Chen, Y., Yu, L., Zhang, X., Shang, J., Fan, J., Zhang, R., Ren, J., & Duan, X. (2022) · Inflammation Research · doi:10.1007/s00011-022-01674-z · Cited by 21
“Moreover, TRAF6 promotes MAPK/AP1 pathway activation and transcription factors C/EBPβ and δ [34, 37, 38, 45] (see Fig.”
BackgroundMicroRNAs and other mechanisms regulate interleukin-17 cytokines and receptors
Mai, J. (2011) · Frontiers in Bioscience-Elite · doi:10.2741/474 · Cited by 19
“Since the complex of IL-17RA and IL-17RC is required for IL-17 and IL-17F signaling(29), and TRAF3IP2 is essential for IL-17 signaling(52, 53), we divided the tissues examined into two tiers based on their expression of IL-17 receptor complexes and TRAF3IP2 (Table 3).”
BackgroundStructural Insights into the Interleukin-17 Family Cytokines and Their Receptors
Liu, S. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-9367-9_5 · Cited by 20
Recent genetic advances in innate immunity of psoriatic arthritis
Hile, G. A., Kahlenberg, J. M., & Gudjonsson, J. E. (2020) · Clinical Immunology · doi:10.1016/j.clim.2020.108405 · Cited by 18
Goedken, E. R., Argiriadi, M. A., Dietrich, J. D., Petros, A. M., Krishnan, N., Panchal, S. C., Qiu, W., Wu, H., Zhu, H., Adams, A. M., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-18760-1 · Cited by 18
Mechanistic Insights into the Roles of the IL-17/IL-17R Families in Pancreatic Cancer
Chen, Z., Qiao, S., Liu, Y., Sun, M., Li, B., Lü, A., & Li, F. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713539 · Cited by 19
“Several studies have demonstrated that IL-17A activates nuclear factor-κB (NF-κB) and ACT1, which plays an important role in inducing inflammation by acting as a membrane-proximal adaptor for the IL-17 receptor [40].”
BackgroundSafwat, S. M., Tohamy, M. E., Aboonq, M. S., Alrehaili, A., Assinnari, A., Bahashwan, A. S., ElGendy, A. A., & Hussein, A. M. (2023) · Brain Sciences · doi:10.3390/brainsci14010012 · Cited by 20
“Additionally, IL-17 induces the synthesis of chemokines and the influx of neutrophils in microglia and astrocytes, which contribute to the onset or progression of MS [9].”
BackgroundLiu, J., Liu, S., Cao, H., Shi, B., Li, Q., Shan, J., Yuan, J., & Lin, J. (2022) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2022/6461560 · Cited by 18
“Among the proteins of the IL-17 signaling pathway, NF-κB activator 1 (Act1/TRAF3IP2) [61, 62], tumor necrosis factor receptor-associated factor 6 (TRAF6) [63], and AP-1 play important roles.”
BackgroundLiu, G., Wu, H., Chen, L., Xu, J., Wang, M., Li, D., & Lu, P. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2017.6623 · Cited by 16
“Although the intracellular signaling pathway and pro‑inflammatory function of IL‑17 are visibly similar to those of Toll and IL-1, IL-17R shares no homology with other receptor sequences, thus IL-17, homologous proteins and their viral homologues can be considered a novel cytokine family (20).”
Zhang, T., Rao, X., Song, S., Tian, K., Wang, Y., Wang, C., Bai, X., & Liu, P. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.128435 · Cited by 16
Ahn, I. E., Ju, J. H., Lee, S., Park, J. S., Oh, H., Kim, H. R., Lee, S. H., Park, S. H., Kim, H. Y., & Cho, M. L. (2012) · Scandinavian Journal of Immunology · doi:10.1111/j.1365-3083.2012.02745.x · Cited by 16
Wang, F., Cui, Y., Shen, X.-L., Wang, S., & Yang, G. (2019) · Microbes and Infection · doi:10.1016/j.micinf.2019.03.003 · Cited by 15
Wang, Y., Fang, M., Wang, X., Liu, W.-Y., Zheng, Y., Wu, X., & Tao, R. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i47.17924 · Cited by 16
Act1, Scene Brain: Astrocytes Play a Lead Role
Rodgers, J. M., Zhou, L. F., & Miller, S. D. (2010) · Immunity · doi:10.1016/j.immuni.2010.03.009 · Cited by 16
“Upon IL-17 binding, the heteromeric transmembrane receptor (IL-17RA and IL-17RC) recruits and interacts with Act1 by its SERIF domains (Chang et al., 2006).”
BackgroundRationalizing heptadecaphobia: TH17 cells and associated cytokines in cancer and metastasis
Lücke, J., Shiri, A. M., Zhang, T., Kempski, J., Giannou, A. D., & Huber, S. (2021) · FEBS Journal · doi:10.1111/febs.15711 · Cited by 14
C-EBPβ mediates in cigarette/IL-17A-induced bronchial epithelial–mesenchymal transition in COPD mice
Chu, S., Ma, L., Wu, Y., Zhao, X., Xiao, B., & Pan, Q. (2021) · BMC Pulmonary Medicine · doi:10.1186/s12890-021-01738-6 · Cited by 15
“increased in COPD, and could be regulated by IL-17A via IL-17R [23, 24].”
BackgroundRen, T., Feng, H., Xu, Y., & Ling, Y. (2024) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2024.118267 · Cited by 13
Gautam, A. S., Panda, E. S., Balki, S., Pandey, S. K., Tiwari, A., & Singh, R. K. (2025) · Food & Function · doi:10.1039/d4fo05278a · Cited by 13
Ryzhakov, G., Blazek, K. D., Lai, C., & Udalova, I. A. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1200428 · Cited by 15
“Act1 seems to be dispensable for IL-1– and LPS-induced gene expression (29), but its role in other cytokine and TLR signaling pathways, including antiviral signaling, has not yet been addressed.”
BackgroundInfluentialIL-17RA in Intestinal Inflammation: Structure, Signaling, Function, and Clinical Application
Liu, S., Ren, J., & Li, J. (2014) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000217 · Cited by 14
“Interestingly, NF-kB seems to be participating in the regulation of both C/EBPb and C/EBPd through the direct association of Rel region in NF-kB with bZIP region in C/EBP.(35,54,55)”
BackgroundNeonatal Pulmonary Host Defense
Good, M. L., Kolls, J. K., & Empey, K. M. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-35214-7.00130-x · Cited by 17
Li, D., Bechara, R., Ramani, K., Jawale, C. V., Li, Y., Kolls, J. K., Gaffen, S. L., & Biswas, P. S. (2021) · JCI Insight · doi:10.1172/jci.insight.147505 · Cited by 12
“HK-2 Δ ZC3H12A cells in which NFKBIZ was silenced showed diminished levels of LCN2 and IL6 mRNA compared with controls (Figure 6B).”
InfluentialArid5a Mediates an IL-17–Dependent Pathway That Drives Autoimmunity but Not Antifungal Host Defense
Taylor, T. C., Li, Y., Li, D., Majumder, S., McGeachy, M. J., Biswas, P. S., Gingras, S., & Gaffen, S. L. (2022) · The Journal of Immunology · doi:10.4049/jimmunol.2200132 · Cited by 14
Chen, C., Zhang, Q., Liu, S., Lambrechts, M., Qu, Y., & You, Z. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00343 · Cited by 13
“The treatment for cells and tissues included: (1) control with vehicle; (2) AZD5363 at 2 μM for 3 h; (3) insulin at 50 ng/ml for 2.”
BackgroundMethodAssociation Between Three SNPs and Thromboangiitis Obliterans in Xinjiang Uyghur Population
Shi, Z., Fang, Q., Limu, S., Jiareke, T., & Ge, X. (2016) · Genetic Testing and Molecular Biomarkers · doi:10.1089/gtmb.2015.0264 · Cited by 12
“IL-17 enhances cytokine and growth factors’ release from resident cells; these factors include IL-6, IL-8, IL-11, granulocyte macrophage colony-stimulating factor, and vascular endothelial growth factor (Chang et al. , 2006, 2011; de Beaucoudrey et al. , 2008; Claudio et al. , 2009).”
Lipovsky, A. I., Slivka, P. F., Su, Z., Wang, Y., Paulsboe, S. E., Wetter, J. B., Namovic, M. T., Gauvin, D. M., Perron, D. C., Gauld, S. B., et al. (2021) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2020.10.029 · Cited by 13
Pires, B. R. B., Binato, R., Ferreira, G. M., Corrêa, S., Rocher, B. D., Bulzico, D., Crocamo, S., dos Santos, E. C., Lima, L. G., & Abdelhay, E. S. F. W. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212144 · Cited by 14
Mouse Th17 cells: Current understanding of their generation and regulation
Dong, C. (2009) · European Journal of Immunology · doi:10.1002/eji.200839076 · Cited by 11
Self-citationZhang, M., Wang, G., Tao, Y., & Zhang, H. (2015) · PubMed · Cited by 12
Increased Act1/IL-17R expression in Hirschsprung’s disease
Tomuschat, C., O’Donnell, A. M., Coyle, D., & Puri, P. (2016) · Pediatric Surgery International · doi:10.1007/s00383-016-3980-4 · Cited by 11
“However, it has been shown that ACT1, a cytoplasmatic protein (60 kDa), physically associates with the IL-17R through its SEFIR domain [15].”
BackgroundKidney-Specific Interleukin-17 Responses During Infection and Injury
Peroumal, D., & Biswas, P. S. (2023) · Annual Review of Immunology · doi:10.1146/annurev-immunol-052523-015141 · Cited by 12
Moon, J. Y., Wolf, S., Joshi, A., Zhang, H., Shadiow, J., Bauer, T. M., Mangum, K. D., Hughes, L. D., Audu, C. O., Melvin, W. J., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-67456-3 · Cited by 12
Evolution of prokaryotic homologues of the eukaryotic SEFIR protein domain.
Wu, B.-J., Gong, J., Liu, L.-L., Li, T.-R., Wei, T., & Bai, Z.-L. (2012) · Gene · doi:10.1016/j.gene.2011.10.033 · Cited by 11
Li, H., Hong, W., Jin, X., Li, G., Zhou, G., & Fan, L. (2019) · FEBS Letters · doi:10.1002/1873-3468.13380 · Cited by 11
Evaluation of Th2 and Th17 Immunity-Related Factors as Indicators of Brucellosis
Gheitasi, R., Keramat, F., Khosravi, S., Hajilooi, M., Pletz, M. W., & Makarewicz, O. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.786994 · Cited by 12
“IL-4 is encoded in one Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 2 gene cluster that includes genes for IL-5 and IL-13 and a locus control region (LCR) (Chang et al., 2006) that regulates the expression of these cytokines (Zeng, 2013).”
BackgroundDiscovery of novel immunopharmacological ligands targeting the IL-17 inflammatory pathway
Álvarez-Coiradas, E., Munteanu, C. R., Saez, L. D., Pazos, A., Huber, K., Loza, M. I., & Domínguez, E. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.107026 · Cited by 12
Pappu, B. P., & Dong, C. (2007) · Current Protocols in Immunology · doi:10.1002/0471142735.im0625s79 · Cited by 10
“For a long time, TH1 and TH2 cells have been considered to represent two mutually exclusive developmental programs undertaken by naive CD4+ T cells upon antigenic stimulation (Mosmann and Coffman, 1989; Dong and Flavell, 2000; Dong, 2006).”
BackgroundSelf-citationLi, X., Zhang, K., Yang, X., Cheng, Y., Huang, S., Deng, W., Hu, Y., Li, T., Duan, H., Mo, X., et al. (2025) · Cellular and Molecular Immunology · doi:10.1038/s41423-025-01325-3 · Cited by 10
“Our fi ndings expand the understanding of the regulatory mechanism of IL-17A/TNF-α signaling in keratinocytes and highlight the therapeutic application of CSBF recombinant protein in psoriasis.”
Tian, J., Bai, Y., You, A., Shen, R., Yan, J., Deng, W., Wen, L., Li, M., & Teng, J. (2019) · Bioscience Reports · doi:10.1042/bsr20190435 · Cited by 9
IL-17 Receptor Signaling: Ubiquitin Gets In On the Act
Levin, S. D. (2009) · Science Signaling · doi:10.1126/scisignal.292pe64 · Cited by 9
“Act1 is recruited to the IL17R complex in a SEFIR domain–dependent manner upon binding of IL-17A to the receptor complex (11, 12).”
BackgroundThe role of interleukin-17 in neurological disorders
Park, S. E., Ferreira, A. F. F., Kwon, H., Yu, J., Diniz, L., Ulrich, H., Britto, L. R. G., & Kim, E. (2025) · Animal Cells and Systems · doi:10.1080/19768354.2025.2510994 · Cited by 9
“ACT1 is an essential mediator protein integral to all recognized IL-17 signaling pathways (Chang et al. 2006; Qian et al. 2007; Liu et al. 2009).”
Hypoxia Primes Human ISCs for Interleukin-Dependent Rescue of Stem Cell Activity
Rivera, K. R., Bliton, R. J., Burclaff, J., Czerwinski, M. J., Liu, J., Trueblood, J. M., Hinesley, C. M., Breau, K. A., Deal, H. E., Joshi, S., et al. (2023) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2023.07.012 · Cited by 11
González-Fernández, C., García-Álvarez, M. Á., & Cuesta, A. (2024) · Marine Life Science & Technology · doi:10.1007/s42995-024-00225-1 · Cited by 9
“SEFIR domain binding to the Act1 adaptor is necessary to transduce the signaling leading to IL-17 regulation of the inflammatory response (Seon et al. 2006).”
Srikanth, M., & Rasool, M. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.108795 · Cited by 11
Coxiella burnetii deubiquitinates host TRAF6 to modulate the macrophage innate immune responsePreprint
Sadi, A., Clemente, T. M., Augusto, L. D. S., Angara, R. K., & Gilk, S. D. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.03.15.532774 · Cited by 9
“Upon ligand binding, Act1 associates with the IL-17 receptor via the conserved SEFIR (Similar Expression of Fibroblast growth factor and IL-17R) domain present in both Act1 and the receptor 11 .”
Zhang, N., Lv, F., Xiao, H., Yi, B., Shao, M., Liang, H., Wang, Y., Wang, Y., Yao, J., Guan, Y., et al. (2023) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2023.115846 · Cited by 7
IL-17 family cytokines in inflammatory or autoimmune skin diseases
Kong, B., & Lai, Y. (2024) · Advances in immunology · doi:10.1016/bs.ai.2024.07.002 · Cited by 8
Lv, F., Song, L.-J., Wang, X., Qiu, F., & Li, X.-F. (2013) · Pharmaceutical Biology · doi:10.3109/13880209.2013.798668 · Cited by 9
“Previous reports (Chang et al., 2006) revealed that IL-17 receptors (IL-17Rs) use Act1 as a membrane-proximal factor to initiate the signaling.”
BackgroundRegulation of Interleukin-17 Production
Dong, W., & Ma, X. (2016) · Advances in experimental medicine and biology · doi:10.1007/978-94-024-0921-5_7 · Cited by 7
Zhang, P. (2015) · Journal of Rheumatic Diseases and Treatment · doi:10.23937/2469-5726/1510024 · Cited by 7
“[26] showed that Actl-mediated activation of NF-κB was dependent on IL-17, constituting an important signal transduction regulator.”
BackgroundStructure of a prokaryotic SEFIR domain reveals two novel SEFIR-SEFIR interaction modes
Yang, H., Zhu, Y., Chen, X., Li, X., Ye, S., & Zhang, R. (2018) · Journal of Structural Biology · doi:10.1016/j.jsb.2018.03.005 · Cited by 7
New Insight into the Possible Roles of L-Carnitine in a Rat Model of Multiple Sclerosis
Safwat, S. M., Aboonq, M. S., Tohamy, M. E., Mojaddidi, M. A., Alqahtani, S. A. M., Zakari, M. O., ElGendy, A. A., & Hussein, A. M. (2023) · Brain Sciences · doi:10.3390/brainsci14010023 · Cited by 6
Act1: A Psoriasis Susceptibility Gene Playing its Part in Keratinocytes
Hobbs, R. P., Smith, S. H., & Getsios, S. (2017) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2017.01.023 · Cited by 6
“F3IP2 small nucleotide polymorphism, resulting in an Act1 Asp10Asn variant, impacting immune surveillance and inflammation would seem relatively straightforward, given the known role of Act1 in dampening IL-17 receptor (IL17R) signaling in mice (Chang et al., 2006; Qian et al., 2007; Wang et al., 2013).”
BackgroundTH17 Cytokines: Characteristics, Regulation, and Biological Function
Angkasekwinai, P., & Dong, C. (2011) · Springer eBooks · doi:10.1007/978-1-4419-9371-7_2 · Cited by 9
“IL-17 does not utilize MyD88 and IRAK4 for cytokine induction (Chang et al. 2006).”
BackgroundInfluentialSelf-citationZhao, R., Ma, Y., Li, S., & Li, J. (2025) · Biomolecules · doi:10.3390/biom15081134 · Cited by 5
“A key mediator in this pathway is Act1, which interacts with IL-17R through its SEFIR domain to activate downstream signaling pathways, including NF-κ B, MAPK, and C/EBP [18, 19] .”
Lu, Y., Xu, F., Qi, F., & Pan, Y. (2026) · Biomolecules · doi:10.3390/biom16030414 · Cited by 5
“The Act1–TRAF6 pathway activation causes standard inflammatory responses through NF-κ B activation via TAK1–IKK complex formation and MAPK pathway activation via ERK, p38 and JNK [25].”
Act1 drives chemoresistance via regulation of antioxidant RNA metabolism and redox homeostasis
Hong, L., Herjan, T., Chen, X., Zagore, L. L., Bulek, K., Wang, H., Yang, C. J., Licatalosi, D. D., Li, X., & Li, X. (2024) · The Journal of Experimental Medicine · doi:10.1084/jem.20231442 · Cited by 5
The Act1 D10N missense variant impairs CD40 signaling in human B-cells
Yu, N., Lambert, S., Bornstein, J. J., Nair, R. P., Enerbäck, C., & Elder, J. T. (2018) · Genes and Immunity · doi:10.1038/s41435-017-0007-7 · Cited by 5
“seen in Act1 D10N mice [7], and yet have been reported to”
BackgroundStructural basis for ACT1 oligomerization induced by IL-17 receptor hetero-tetramer
Zhang, H., Bai, X.-C., & Zhang, X. (2025) · Nature Communications · doi:10.1038/s41467-025-67536-4 · Cited by 4
“As shownbypreviousstudies,ACT1couldco-immunoprecipitatewiththe IL-17 receptors from these cells without IL-17 treatment, likely due to constitutive low levels of secretion of the IL-17 ligands by these cells 16,20 .”
Paine, L. W., Higham, J. P., Barker, K. H., Pavlou, S., Welsh, F., Smith, E. S. J., & Bulmer, D. C. (2025) · Journal of Neurochemistry · doi:10.1111/jnc.70191 · Cited by 5
Munshi, A. R., Wang, T., Takamori, Y., Ando, T., Yokoyama, T., Fuji, D., Xu, Z., Vedi, S., Yamamoto, M., Tsukamoto, K., et al. (2023) · Bioscience Biotechnology and Biochemistry · doi:10.1093/bbb/zbad170 · Cited by 4
Xu, R., Huang, F., Liu, Q., Lv, Y., Hu, L., & Zhang, Q. (2024) · Renal Failure · doi:10.1080/0886022x.2024.2338932 · Cited by 3
“The immune response in anti-GBM GN is primarily mediated by Th1 and Th17 cells, while Th2 cells exert a protective effect [34].”
BackgroundMonteleone, G., Marafini, I., & Troncone, E. (2017) · Wiley-VCH eBooks · doi:10.1002/9783527692156.ch22 · Cited by 3
Functional characterization of interleukin 17 family members and their receptors in amphioxus
Li, H., Zhang, L., Yao, Z., Wang, H., Dong, X., Wang, L., Wang, S., & Gao, Z. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.143901 · Cited by 4
The Role of Secukinumab in The Treatment of Ankylosing Spondylitis
Shah, R., Perry, L., & Deodhar, A. A. (2015) · Immunotherapy · doi:10.2217/imt.15.93 · Cited by 3
Metadata
- Authors
- Chang, S. H., Park, H., & Dong, C.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- University of Washington (US)
- Corresponding author
- Dong, Chen
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2006-11
- Volume
- 281
- Issue
- 47
- Pages
- 35603-35607
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W221516563
- Cited by
- 356
- References
- 17
- Citations by year
- 2026: 11 · 2025: 14 · 2024: 8 · 2023: 16 · 2022: 16 · 2021: 19 · 2020: 14 · 2019: 16 · 2018: 12 · 2017: 17 · 2016: 14 · 2015: 20 · 2014: 21 · 2013: 24 · 2012: 23
- FWCI
- 7.18
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 5082 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › NF-κB Signaling Pathways
- Life Sciences › Immunology and Microbiology › Immunology › Cytokine Signaling Pathways and Interactions
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Keywords
- interleukin-17 receptor, IL-17 signaling, NF-κB activation, C/EBPβ, C/EBPδ, chemokine expression, fibroblasts, inflammatory gene expression
- MeSH terms
- Animals, Humans, Inflammation, Mice, Inbred C57BL, Nuclear Proteins, Phylogeny, Protein Binding, Transcription, Genetic, Signal Transduction, CD4-Positive T-Lymphocytes, Protein Structure, Tertiary, MAP Kinase Signaling System, Adaptor Proteins, Signal Transducing, Mice, Receptors, Interleukin-17
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.